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Abstract
Objectives To evaluate the cost effectiveness of onabo-
tulinumtoxinA (BOTOX, 200 units [200 U]) for the
management of urinary incontinence (UI) in adults with
neurogenic detrusor overactivity (NDO) due to subcervical
spinal cord injury or multiple sclerosis that is not ade-
quately managed with anticholinergic drugs (ACHDs).
Perspective UK National Health Service (NHS)
perspective.
Methods A Markov state-transition model was devel-
oped, which compared onabotulinumtoxinA ? best sup-
portive care (BSC) with BSC alone (comprising
behavioural therapy and pads, alone or in combination
with clean intermittent catheterization and possibly with
ACHDs). Non-responders were eligible for invasive
procedures. Health states were defined according to the
reduction in UI episodes. Efficacy data and estimates of
resource utilization were pooled from 468 patients on
onabotulinumtoxinA in two phase III clinical trials. Drug
costs (2013) and administration costs (NHS Reference
Costs 2011–2012) were obtained from published sources.
The time horizon of the model was 5 years, and costs
and benefits were discounted at 3.5 %. Scenario, one-
way and probabilistic sensitivity analyses (PSAs) were
conducted to explore uncertainties around the
assumptions.
Results In the base case, treatment with onabotulinum-
toxinA ? BSC over 5 years was associated with an
increase in costs of £1,689 and an increase in quality-
adjusted life-years (QALYs) of 0.4, compared with BSC
alone, resulting in an incremental cost-effectiveness ratio
of £3,850 per QALY gained. Sensitivity analyses showed
that utility values had the greatest influence on model
results. PSA suggests that onabotulinumtoxinA ? BSC
had a 100 % probability of being cost effective at a will-
ingness to pay of \£20,000.
Conclusion For adult patients with NDO who are not
adequately managed with ACHDs, onabotulinumtoxin-
A ? BSC appears to be a cost-effective use of resources in
the UK NHS.
Electronic supplementary material The online version of this
article (doi:10.1007/s40273-014-0245-8) contains supplementary
material, which is available to authorized users.
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Key Points for Decision-Makers
OnabotulinumtoxinA (BOTOX, 200 U) ? best
supportive care (BSC) has been shown to
significantly reduce the number of urinary
incontinence (UI) episodes in adult patients with
neurogenic detrusor overactivity (NDO) due to
spinal cord injury or multiple sclerosis that is not
adequately managed with anticholinergic drugs.
OnabotulinumtoxinA ? BSC is associated with a
utility benefit that reflects the reduction in the
number of UI episodes experienced by patients.
The addition of onabotulinumtoxinA to BSC for the
treatment of adult patients with NDO appears to be a
cost-effective intervention in the UK setting,
according to the options analysed in the base-case
model (base-case incremental cost-effectiveness
ratio [ICER] £3,850 per quality-adjusted life-year
[QALY] gained).
The results remained robust, with the ICER
remaining below £20,000 per QALY, across all
probabilistic sensitivity analyses and sensitivity
analyses.
1 Introduction
Any abnormality in bladder control as a consequence of a
neurological disease is generally classified as neuropathic
bladder dysfunction. This disorder mainly affects urine
storage, particularly in patients who exhibit a loss of upper
motor neurone control—for example, in spinal cord injury
(SCI) and multiple sclerosis (MS) [1]. Symptoms of
impaired urine storage include increased frequency of
urination, urinary incontinence (UI) and urgency [1].
Urodynamic assessment is used to confirm the presence of
detrusor overactivity, which is termed ‘neurogenic detrusor
overactivity’ (NDO) in a population with an underlying
neurological condition [2]. NDO has a significant impact
on health-related quality of life (HRQoL); patients com-
monly report detriments in physical function, emotional
wellbeing and social relationships [1, 3]. The economic
burden of UI due to NDO is substantial [3].
Current best practice is based on National Institute for
Health and Care Excellence (NICE) guidelines for the
management of UI in neurological disease [1, 4], which
recommend behavioural therapy, use of incontinence pads,
clean intermittent self-catheterization (CIC) and treatment
of adverse events (AEs) [1, 4]. Together, these are classified
as best supportive care (BSC). In addition, the use of anti-
cholinergic drugs (ACHDs), onabotulinumtoxinA (BO-
TOX, 200 units [200 U]) and augmentation cystoplasty
are also recommended as potential treatment options [1, 4].
Many patients fail to improve with ACHDs, either because
of lack of efficacy or because they develop AEs (for
example, dry mouth, constipation or blurred vision) [5].
High discontinuation rates and interruptions in ACHDs
suggest that patients with NDO are not being offered ade-
quate options to manage their UI [6, 7]. Patients whose
NDO is not adequately managed with ACHDs, or in whom
ACHDs are poorly tolerated, either continue with BSC
alone or receive a combination of onabotulinumtoxin-
A ? BSC [1, 4]. Augmentation cystoplasty can be under-
taken for refractory patients. This procedure is effective,
with good long-term results [8, 9], but is expensive and can
have long-term complications [8]. Thus, onabotulinumtox-
inA ? BSC can become a treatment option for those
patients who are refractory to ACHDs [1, 4].
The primary evidence supporting the use of onabotuli-
numtoxinA ? BSC in adults with NDO comes from the
pooled intention-to-treat (ITT) population of two pivotal
phase III studies (NCT00461292 and NCT00311376;
http://www.clinicaltrials.gov) [10, 11]. The pooled popu-
lation included 468 adults with C14 UI episodes/week due
to MS (n = 261) or SCI (n = 207), receiving onabotuli-
numtoxinA 200 U (n = 227) or placebo (n = 241). All
patients received BSC. Most baseline characteristics were
comparable between the aetiology groups; however, dif-
ferences included gender (the majority [71 %] of SCI
patients were male; the majority [82 %] of MS patients
were female), baseline CIC use (SCI: 84.8 %; MS: 29.4 %)
and baseline ACHD use (SCI: 60.0 %; MS: 50.7 %) [12].
The results of the clinical trials demonstrated that onabo-
tulinumtoxinA significantly reduced the number of UI
episodes and improved urodynamic parameters and quality
of life (QoL) relative to placebo. The reduction in the
number of UI episodes in patients receiving onabotuli-
numtoxinA was more than double that observed in pla-
cebo-injected patients (mean change from baseline to
week 6: -21.3 versus -10.5 episodes [p \ 0.001]; from
baseline to week 12: -20.6 versus -9.9 episodes
[p \ 0.001]). QoL, as measured using the Incontinence
Quality of Life (I-QOL) questionnaire total score at weeks
6 and 12, was improved threefold in onabotulinumtoxinA-
treated patients, compared with those receiving placebo
(p \ 0.001) [12].
The aim of this economic evaluation was to assess the
cost effectiveness, from the perspective of the UK National
Health Service (NHS), of onabotulinumtoxinA ? BSC
compared with BSC alone for the management of UI in
adult patients with NDO who are not adequately managed
with ACHDs.
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2 Methods
An existing Markov model was adapted for the UK [13].
The analysis employed a Markov state-transition model
(written in Microsoft Excel [Redmond, WA, USA]) to
estimate the costs per quality-adjusted life-year (QALY) of
onabotulinumtoxinA 200 U ? BSC for the treatment of UI
in patients with NDO (due to MS or SCI), who are not
adequately managed on ACHDs, over a 5-year time
horizon.
2.1 Data Sources
A review of the published literature, using systematic
methodology, was conducted.1 The following databases
were searched (January 2000–February 2011): BIOSIS
Preview, EMBASE, EMBASE Alert, SciSearch and
MEDLINE. Relevant terms for the condition (specifi-
cally, ‘urinary incontinence due to NDO’) were crossed
with outcome concepts, study type concepts and interven-
tion concepts, as appropriate. If evidence from published
sources was not available, expert opinion was sought via
advisory panel and survey.
2.2 Treatments Modelled
Treatment effect was measured using patient-reported
diary data on UI episodes over a 7-day period prior to
each study visit. Efficacy and safety estimates of onab-
otulinumtoxinA and BSC were based on data within the
first 12 weeks after treatment initiation from the pooled
ITT population from two phase III, randomized, con-
trolled trials (RCTs) [10–12]. Patient-level data files
from each of the trials were combined in order to pool
the data. Week 12 was the furthest time point after
treatment initiation at which randomization integrity was
maintained; after this point, the high degree of crossover
became problematic for obtaining unbiased estimates
(crossover was driven by patient requests for re-treat-
ment) [12].
Patients in the onabotulinumtoxinA arm who responded
(C50 % reduction in weekly UI episodes from baseline) to
treatment by week 12 were assumed to be re-treated every
9 months, on the basis of data from the phase III trials [12].
Subsequent treatments with onabotulinumtoxinA were
assumed to produce the same duration of effect and
efficacy.
Data from the placebo arms of the pooled ITT popula-
tion from two phase III RCTs were used to approximate
BSC treatment in clinical practice. The placebo arms in the
phase III trials were deemed appropriate to inform the BSC
arm of the model, since all patients who were receiving
ACHDs when they started the trial were required to remain
on the ACHD at the baseline dose for the remainder of the
trial [12]. In addition, they could initiate CIC at the dis-
cretion of the physician, and they used incontinence pads
as needed [12]. In clinical practice, patients receiving BSC
(alone or in combination) may stop, restart, switch or use
multiple concomitant ACHDs, and/or titrate to higher
doses. Although this was not permitted in the trial, the
participants had experienced NDO for some time, and
therapy with ACHD was likely to be optimized already
[12]. As the placebo in the trial was administered via
injection, the efficacy of this placebo injection was likely to
have been greater than the efficacy of BSC in actual clin-




The modelled treatment pathway incorporated a compari-
son of onabotulinumtoxinA ? BSC with BSC alone. Non-
responders would continue to receive BSC and, after
36 weeks, a proportion (5 %) of these were assumed to
undergo bladder surgery (augmentation cystoplasty) [14].
The commonly used Markov state-transition approach
[15] was selected in favour of individual cycle-level tran-
sitions among the health states after week 12, because of
difficulties with the high level of crossover in the BSC
group in the pivotal studies [12]. A 5-year time horizon,
with a model cycle length of 6 weeks, was used in the base
case. This time horizon was selected on the basis of data
from the two phase III trials and longer-term data sug-
gesting that patients continue to gain benefit from onabo-
tulinumtoxinA with repeated injections [10–12, 16, 17].
Lifetime (60-year) treatment outcomes were assessed in a
sensitivity analysis. Outcome measures were QALYs,
lifetime costs and incremental cost-effectiveness ratios
(ICERs).
The model included six health states based on a reduc-
tion in weekly UI episodes, which is commonly used to
determine treatment effects in UI: (1) \50 % reduction
(non-responders); (2) C50–99 % reduction (non-dry
responders); (3) 100 % reduction (dry); (4) post-surgery
dry (100 % reduction); (5) post-surgery non-dry respond-
ers (C50–99 % reduction); and (6) death. Patients entered
the model on day 1 and then cycled among the health states
every 6 weeks. It was assumed that all patients could be in
only one state at any time. The definition of health states is
in line with published literature, whereby a C50 %
reduction in UI episodes would represent treatment success
1 Further details of the literature review that was completed are
available from the corresponding author on request.
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[10, 11, 16]. Figure 1 shows disease progression in this
Markov state-transition model.
Patient-level data were then used to develop transition
probabilities for the transitions between baseline, week 6
and week 12 health states for the onabotulinumtoxin-
A ? BSC and BSC arms. The transition was assumed to
occur directly after initiation of treatment. Transition
probabilities for patients post-surgery were based on pub-
licly available literature [8, 18]. Transitions to the death
state were calculated from general population mortality
rates in the UK life tables.
A flexible rate of discontinuation was applied in the
model, starting from the first onabotulinumtoxinA treat-
ment. In the absence of other available evidence,
assumptions regarding annual discontinuation rates were
based on the discontinuation rate among responder
patients in the pivotal studies (that is, among patients who
were treated with onabotulinumtoxinA and responded to
treatment [C50 % reduction in UI episodes] at week 12)
and included discontinuations due to lack of efficacy,
AEs, pregnancy, and personal or other reasons that may
occur in clinical practice (drop-out rates: 5.73 % in the
onabotulinumtoxinA group and 11.43 % in the BSC
group). This was operationalized in the model in a con-
servative manner by moving patients from the dry to the
non-dry responder health state and by moving patients
from the dry and non-dry responder health states to the
non-responder health state. Assumptions used around
treatment discontinuation were tested in sensitivity
analysis.
The analysis was conducted from the perspective of the
UK NHS and Personal Social Services, and incorporates
utilities and costs associated with receiving treatment for
clinical symptoms. All indirect and non-medical costs were
excluded from this analysis. All costs included in the cost-
effectiveness model were in British pounds sterling (£), and
costs and benefits beyond the first year were discounted
annually at a rate of 3.5 %, in accordance with methods
guidance from NICE [19].
2.3.2 Model Validation
Internal validity was evaluated by subjecting the model to
thorough debugging, using null and extreme input values,
and a detailed review of all mathematical formulas and
coding by both internal and external reviewers. External
validation of model inputs and assumptions was gained via
an advisory board panel, comprising seven members (cli-
nicians, pharmacists and policy makers). The panel
reviewed the clinical and economic data and related
assumptions for relevance and their validity in clinical
practice.
2.4 Model Parameters
All key parameters are summarized in Table 1.
2.4.1 Adverse Events
Urinary tract infections (UTIs; symptomatic and asymp-
tomatic) were modelled as AEs. The UTI rate was esti-
mated from the phase III trials [12] as an event rate per
patient-year at week 12 (placebo-controlled data), taking
into account the total number of UTIs from baseline to
week 12. Standard error (SE) was calculated using the
bootstrap method with a sample of 1,000. The mean
number of UTIs per model cycle was determined by
dividing the mean yearly rate by 8.
Fig. 1 Disease progression in
the Markov state-transition
model
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Table 1 Model parameters
OnabotulinumtoxinA 200 U BSC References
Utility assumptions
Mean utilities (UK weighted)
Dry 0.562 0.562 Cuervo et al. [21]
Non-dry responder 0.435 0.435 Cuervo et al. [21]
Non-responder 0.240 0.240 Cuervo et al. [21]
Clinical and resource use assumptions
Average time to onabotulinumtoxinA re-treatment (months) 8.94 – Carlson et al. [13]a
Health state proportions, week 6
Dry 0.370 0.091 Carlson et al. [13]a
Non-dry responder 0.388 0.295 Carlson et al. [13]a
Non-responder 0.242 0.614 Carlson et al. [13]a
Health state proportions, week 12
Dry 0.363 0.079 Carlson et al. [13]a
Non-dry responder 0.408 0.272 Carlson et al. [13]a
Non-responder 0.229 0.649 Carlson et al. [13]a
Proportion using ACHDs
Dry 0.54 (0.054) 0.61 (0.061) Carlson et al. [13]a
Non-dry responder 0.58 (0.058) 0.56 (0.056) Carlson et al. [13]a
Non-responder 0.43 (0.043) 0.60 (0.060) Carlson et al. [13]a
Mean CICs per month
Dry 81.91 54.98 Carlson et al. [13]a
Non-dry responder 86.34 69.52 Carlson et al. [13]a
Non-responder 68.49 85.17b Carlson et al. [13]a
Post-surgery non-responder 60.86 – Carlson et al. [13]a
Mean UTIs per month
Dry 0.0415 0.0294 Allergan Ltdc
Non-dry responder 0.0452 0.0163 Allergan Ltdc
Non-responder 0.0601 0.0333 Allergan Ltdc
Annual proportion of patients who drop out from treatment and move to non-responder health stated
Dry 2.5 % 5.2 % Allergan Ltdc
Non-dry 3.2 % 6.2 % Allergan Ltdc
Health state definitions: dry, 100 % reduction in weekly UI episodes; non-dry responder, C50–99 % reduction in weekly UI episodes; non-
responder, \50 % reduction in weekly UI episodes; post-surgery non-responder, C50–99 % reduction in weekly UI episodes
ACHD anticholinergic drug, AE adverse event, BSC best supportive care, CIC clean intermittent self-catheterization, UI urinary incontinence,
UTI urinary tract infection
a Transition probabilities were derived by using patient-level data from the phase III trials (NCT00461292 and NCT00311376)
b Transition probabilities were derived by using patient-level data from the phase III trials (NCT00461292 and NCT00311376); data not
published
c Data for mean UTIs per month and annual proportion of patients who drop out from treatment and move to non-responder health state, pooled
phase III trials (NCT00461292 and NCT00311376); data not published
d In the absence of other available evidence, assumptions regarding annual discontinuation rates were based on the discontinuation rate among
responder patients in the pivotal studies (i.e. among patients who were treated with onabotulinumtoxinA and responded to treatment [C50 %
reduction of UI episodes] at week 12). Discontinuations due to lack of efficacy, AEs, pregnancy, and personal or other reasons that may occur in
clinical practice were included in the drop-out rate (5.73 % in the onabotulinumtoxinA group and 11.43 % in the BSC group). This was
operationalized in the model in a conservative manner by moving patients from the dry health state to the non-dry responder health state and by
moving patients from the dry and non-dry responder health states to the non-responder health state
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2.4.2 Utilities
The EuroQol Five Dimensions (EQ-5D) and Short
Form 36 (SF-36) questionnaires were administered in the
pivotal studies at baseline and on study exit only; therefore,
these utility values could not be used in the model. Con-
sequently, utility values for the model were derived from
the I-QOL questionnaire [20], which was administered in
the pivotal studies [12]. A two-stage process was used to
develop the condition-specific Incontinence Utility Index
from the I-QOL questionnaire and its neurogenic model
[21].
The utility values correspond with treatment and
response status (Table 1). Because of the lack of available
literature reporting utilities associated with the health states
post-surgery, post-surgery dry and non-dry responders
were assumed to have the same utilities as dry and non-dry
responders, respectively.
Time-dependent weighting of the utility scores for
responding patients in both groups allowed the data from
the entire course of the trial to be modelled and allowed the
relevant impact on QALYs to be captured. This weighting
was related to the possible loss of efficacy over time that
was experienced by patients in the onabotulinumtoxinA
200 U group and that would precede the request for re-
treatment, and the loss of placebo effect in the comparator
arm. The distribution of patients within each health state at
weeks 6 and 12 was taken from the pivotal studies to
inform the utilities at these time points. In order to inform
the rate of subsequent degradation, the weighted average of
the health state distributions at weeks 18, 24, 30 and 36
was used to calculate the average utility for each cohort up
to the mean time to request re-treatment. Given the mean
time to re-treatment of nine months (8.94) in patients who
respond to onabotulinumtoxinA at week 12, week 36 was
selected to accommodate a model cycle duration of
6 weeks.
Disutilities due to AEs from drug treatment were not
modelled, because of the limited evidence in the NDO
population. AEs were, therefore, accounted for in the
model only in terms of costs.
2.4.3 Resource Use and Costs
Resource use data were derived from the studies as far as
possible and supplemented with values from a literature
review. However, as published data were not available for
both the proportion of non-responding patients receiving
augmentation cystoplasty and the number of additional
physician visits for treating UI, these estimates were vali-
dated via an advisory board panel.
The cost of treatment in the onabotulinumtoxinA arm
of the model included the per-unit cost of
onabotulinumtoxinA (200 U vial: £276.40) and consultant
time to administer the injection (see Table 2) [22, 23]. On
the basis of the mean time to request re-treatment from
the phase III trials (8.94 months), responders were
assumed to receive re-treatment, on average, every
9 months. BSC treatment was not associated with any
intervention costs.
Resource use and costs associated with UI and man-
agement of AEs were applied to both the onabotulinum-
toxinA and BSC arms. Resource use (use of ACHDs, use of
incontinence pads, drug administration, use of CIC and
treatment of UTIs with antibiotics) was estimated from the
two phase III trials. Other resource use was estimated using
results from a qualitative survey of UK specialist physi-
cians (details are provided in Online Resource 1 in the
Electronic Supplementary Material).
Resource use and costs associated with surgical inter-
vention included the cost of surgery. Given the limited
evidence on AEs associated with augmentation cystoplasty
in patients with NDO, these were not taken into account in
the base-case analysis.
2.5 Sensitivity Analyses
One-way sensitivity analyses and probabilistic sensitivity
analyses (PSAs) were performed by varying effectiveness,
utility and cost parameters.
Parameter uncertainty was assessed in a PSA [24]. Beta
distributions were fitted for patient distributions and health-
related utility data; gamma distributions were fitted for all
cost parameters; and normal distributions were fitted to
sample mean frequency estimates (for example, mean
number of UI episodes, physician visits). Each point esti-
mate was associated with a respective SE. Where the SE
was not available, a variation of ±10 % was assumed.
Values used in the PSA were derived by random sampling
from respective distributions. PSA results were generated
from 1,000 iterations. Distribution parameters, as well as
probabilistic values from one random sampling, are pro-
vided in Online Resource 2 in the Electronic Supplemen-
tary Material.
A range of scenario analyses were conducted to account
for the uncertainty of cost effectiveness associated with
assumptions relating to clinical practice, costs and esti-
mates of the value of health outcomes.
3 Results
The onabotulinumtoxinA ? BSC group incurs lower
healthcare resource utilization than the BSC group. A
smaller number of UI episodes in the onabotulinumtoxin-
A ? BSC group means reduced use of incontinence pads
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and fewer physician visits, compared with the BSC group.
Corresponding with the reduced resource utilization,
healthcare costs are reduced with the onabotulinumtoxin-
A ? BSC group over the 5-year time horizon. Resource
utilization and disaggregated costs for the base-case anal-
yses are provided in Table 3, and estimates of total costs
per health state (per patient) at year 5 are provided in
Table 4. Over the 5-year time horizon, it is estimated that a
mean of 516 UI episodes (per person-year) would be
avoided at a cost of £3 per episode.
Over a 5-year time horizon, treatment with onabotuli-
numtoxinA ? BSC was associated with an increase in
costs of £1,689 (£8,735 versus £7,046) and an increase of
0.4388 in discounted QALYs gained (1.7236 versus
1.2848) compared with BSC alone. These results generated
an ICER of £3,850 per QALY gained (Table 5).
Table 2 Summary of unit costs used in the model
Parameter Resource use Unit
cost
References




Day case average cost £292 NHS Reference Costs
2011–2012 [23]
Consultation cost at initiation of
onabotulinumtoxinA
Urology outpatient attendance £103 NHS Reference Costs
2011–2012 [23]
Administration cost of BSC Urology outpatient consultation £103 NHS Reference Costs
2011–2012 [23]
Cost of ACHDs Monthly cost of oxybutynin 5 mg 3 times daily for 28 days £11.60 British Medical
Association [22]
Cost of incontinence pads Cost per pad £0.25 NICE Clinical
Guideline 148 [1]
Cost of CIC Cost per catheterization £0.75 NICE Clinical
Guideline 148 [1]
Cost of UTI treatment Augmentin 375 mg 21-pack; cost per course £4.19 British Medical
Association [22]
Cost of follow-up urologist visits Urology outpatient consultation £103 NHS Reference Costs
2011–2012 [23]
Cost of surgerya Elective inpatient LB10Z (major open bladder procedure or
reconstruction, age 19 years and older)
£5,847 NHS Reference Costs
2011–2012 [23]
ACHD anticholinergic drug, BSC best supportive care, CIC clean intermittent self-catheterization, NICE National Institute for Health and Care
Excellence, UTI urinary tract infection
a Augmentation cystoplasty
Table 3 Base-case analysis: costs in detail
OnabotulinumtoxinA ? BSC BSC Incremental cost
Study drug costs £1,478 £0 £1,478
Administration costs £1,561 £205 £1,355
Total direct study drug healthcare costs £3,038 £205 £2,833
Additional physician visits £1,154 £1,517 -£363
Incontinence pad costs £716 £1,286 -£570
CIC costs £3,397 £3,454 -£57
ACHD costs £353 £396 -£43
UTI costs £12 £7 £5
Non-responder surgical intervention costs £66 £181 -£115
Total healthcare costs £5,697 £6,841 2£1,143
Total NHS perspective costs £8,735 £7,046 £1,689
Five-year time horizon in people with UI inadequately managed with ACHDs
ACHD anticholinergic drug, BSC best supportive care CIC clean intermittent self-catheterization, NHS National Health Service, UI urinary
incontinence, UTI urinary tract infection
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3.1 Scenario Analyses
Scenario analyses are presented in Table 6. Results from
the scenario analyses indicate that the ICER is sensitive to
a shorter time horizon; a reduced number of urologist
attendances by non-responders; a shorter mean time inter-
val between requests for onabotulinumtoxinA re-treatment;
the rate of utility degradation related to onabotulinumtox-
inA re-treatment; and adopting one urodynamic assessment
for non-responders and non-dry responders subsequent to
initial treatment. All of these analyses increased the ICER
relative to the base case to more than £4,000. For other
analyses (Table 6), the ICER did not exceed £4,000. No
scenario exceeded the willingness-to-pay threshold of
£20,000/QALY.
3.1.1 Underlying Condition: Spinal Cord Injury
or Multiple Sclerosis
Given the difference in the cause of NDO between MS and
SCI patients, it was assumed that each would incur dif-
ferent resource uses and hence costs for the management of
NDO. In addition, analyses of the pivotal trials show a
difference in time to request re-treatment between MS and
SCI patients (the mean re-treatment intervals are
9.224 months and 8.532 months for MS and SCI patients,
respectively). These re-treatment intervals were used in the
subgroup analyses.
For the 5-year time horizon, onabotulinumtoxin-
A ? BSC compared with BSC alone yielded an ICER of
£6,422/QALY and £1,767/QALY for MS and SCI,
respectively. Although similar findings were noted for both
aetiologies in terms of improved QALYs, total costs in
both treatment groups were considerably higher for the SCI
population than for the MS population. This was mainly
driven by higher costs associated with greater CIC use in
SCI patients in both the onabotulinumtoxinA ? BSC and
BSC groups. Despite this, lower incremental costs for SCI
compared with MS resulted in a lower ICER for SCI.
3.2 Sensitivity Analyses
One-way sensitivity analyses were applied to the model in
order to ascertain the cost effectiveness of onabotulinum-
toxinA ? BSC. Variations in assumptions regarding costs
and outcomes were examined in order to establish the key
drivers of the model and to verify the robustness of the
primary results. Sensitivity analyses involving health out-
comes and cost variables are shown in Fig. 2. Cost effec-
tiveness was sensitive to the utility values used for the
health states. As there is no benefit from reduced mortality,
all QALY gains result from improvements in HRQoL as a
result of fewer weekly UI episodes. The results also indi-
cated that the main drivers of cost in the model are mean
CIC and treatment administration costs. PSA indicated
that, at a willingness to pay of £20,000 per QALY, onab-
otulinumtoxinA has a 100 % probability of being cost
effective (Figs. 3, 4).
4 Discussion
The model presented here, which is adapted from the US
model by Carlson et al. [13], assessed the cost effectiveness
of onabotulinumtoxinA ? BSC versus BSC alone for the
treatment of UI in adult patients with NDO (due to SCI or
MS) who are not adequately managed on ACHDs in the
Table 4 Base-case analysis: estimated total costs per health state (per
patient at year 5)









BSC best supportive care
Table 5 Results of base-case analysis
OnabotulinumtoxinA ? BSC BSC Incremental cost
Total costs £8,735 £7,046 £1,689
Life-years 4.42 4.42 0
QALYs 1.7236 1.2848 0.4388
ICER (£/QALY gained) £3,850
Five-year time horizon in people with UI inadequately managed with ACHDs
ACHD anticholinergic drug, BSC best supportive care, ICER incremental cost-effectiveness ratio, QALY quality-adjusted life-year, UI urinary
incontinence
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Table 6 Scenario analyses
Scenario Key assumptions ICER




Other assumptions remain unchanged
Time horizon reduced to 1 year
Other assumptions remain unchanged
£6,737
Time horizon to 12 weeks
The analysis allowed within-trial analysis based on placebo-controlled data
£18,737
Analysis by underlying condition Patients with NDO due to MS £6,422
Patients with NDO due to SCI £1,767
Discount rate Costs and effects not discounted £3,779
Costs and effects discounted at 6 % £3,887
Resource utilization Reducing the number of urologist visits for non-responder patients from 4
to 2
Assumes that a non-responder would visit the urologist the same number of
times as a patient in a responder health state
£4,677
Reducing the number of urologist visits for non-responder patients from 4
to 3
Assumes that a non-responder would visit the urologist the same number of
times as a patient in a responder health state
£4,264
Cost of urodynamic assessment in patients with no relief or partial relief of
their symptoms (non-responders and non-dry responder patients)
£4,173
Non-responder treatment Altering the proportion of non-responders receiving augmentation
cystoplasty
Reducing the proportion from 5 % to 2 % £3,828
Increasing the proportion from 5 % to 7 % £3,871
Assumes that a non-responder would visit the urologist the same number of
times as a patient in a responder health state
AEs associated with augmentation cystoplasty Modelling AEs associated with augmentation
Applying costs associated with AEs as per NHS Reference Costs 2009–2010 (in
line with NICE guidelines)
£3,820
ACHD therapy All dry (100 % reduction) and responding patients (‡50–99 % reduction)
stop ACHD therapy at week 12
£3,484
Mean time to request onabotulinumtoxinA 200 U
re-treatment
Decrease and increase of onabotulinumtoxinA 200 U re-treatment time
Mean time to request re-treatment decreased to 7.16 months (assumed as an
absolute minimum mean time to request re-treatment)
£5,194
Mean time to request re-treatment increased to 11.26 months (assumed as a
maximum value for mean time to request re-treatment based on 2-year data)
£2,739
Change in utility scores Change of utility values so that utility scores are based on health states and
differ by treatment arm
£2,489
Change in the rate of utility degradation related to
onabotulinumtoxinA 200 U re-treatment
Varying the rate of decrease in onabotulinumtoxinA 200 U benefits
associated with the need for subsequent re-treatment
The rate of change in health condition (prior to re-treatment) assumed to be
identical to that of patients in the BSC arm
£4,737
Change of cost of ACHD therapy Varying the cost of ACHD therapy £3,729
OnabotulinumtoxinA administration costs Costs of onabotulinumtoxinA administration removed
These costs are largely fixed and rarely lead to cash-realising savings or
increased costs
£413
ACHD anticholinergic drug, AE adverse event, BSC best supportive care, ICER incremental cost-effectiveness ratio, MS multiple sclerosis,
NDO neurogenic detrusor overactivity, NHS National Health Service, NICE National Institute for Health and Care Excellence, SCI spinal cord
injury
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UK. In the base-case analysis, onabotulinumtoxin-
A ? BSC represented a cost-effective alternative com-
pared with BSC alone, at a cost of £3,850 per QALY
gained. In the absence of long-term data, best possible
assumptions were made. Uncertainty surrounding these
assumptions was tested in PSA and scenario analyses. PSA
demonstrated that, at a willingness to pay of £20,000/
QALY gained, onabotulinumtoxinA has a 100 % proba-
bility of being cost effective; this remained robust in sce-
nario analyses. The model was assessed by the All Wales
Medicines Strategy Group (AWMSG) and the Scottish
Medicines Consortium (SMC), who both accepted
onabotulinumtoxinA 200 U for use within this population
[25, 26]. The results are also in agreement with a cost-
consequence study conducted from a UK NHS perspective,
which concluded that onabotulinumtoxinA was cost
effective in both idiopathic and neurogenic disease [27].
Although onabotulinumtoxinA is cost effective in both
the MS and SCI subgroups, the clinical benefits and costs
differ by aetiology. The model suggested that the cost
effectiveness was greatest for SCI patients receiving on-
abotulinumtoxinA ? BSC, yielding an ICER of £1,767.
For MS, similar findings were noted with respect to a
reduction in the number of UI episodes and improved
QALYs; however, higher incremental costs resulted in an
ICER of £6,422. The profile of the SCI population is the
main driver of this difference in outcomes—a higher rate of
CIC use in the BSC arm means that the incremental cost of
CIC use in the onabotulinumtoxinA arm of the model is
lower.
As the phase III trials were international, multicentre
studies, clinical results would be expected to be general-
izable to other countries. The rates of resource utilization
and costs, however, may need adapting in order to be rel-
evant to other countries.
This cost-effectiveness analysis has some limitations.
There are no relevant active comparators for onabotuli-
numtoxinA, because patients comprising the target popu-
lation have already failed on conservative
pharmacotherapy with ACHDs but have not yet undergone
more invasive procedures. For these patients, the treatment
choices are to continue with BSC alone or to add
Fig. 2 Univariate sensitivity analyses. BSC best supportive care, CIC clean intermittent self-catheterization, SD standard deviation, UTI urinary
tract infection
Fig. 3 Scatter plot of probabilistic sensitivity analysis. QALY qual-
ity-adjusted life-year
390 R. Hamid et al.
onabotulinumtoxinA to BSC. Continued management with
BSC was, therefore, considered to be the appropriate
clinical comparator for the purposes of this economic
analysis. In the trials, patients continued on ACHDs (if
used at baseline), catheters and incontinence pads. The
placebo arm achieved results that may not be matched in
clinical practice, with almost 40 % of patients achieving a
[50 % reduction in UI at 12 weeks [14]. This model
assumes that the efficacy of BSC in clinical practice is
similar to the efficacy of placebo injections in the pooled
BSC groups from the trials. As the placebo in the trial was
an injection, this was likely to have been greater than the
efficacy of BSC in actual clinical practice and, as such, it
was considered to be a conservative approach.
Utility values used in this model ranged from 0.240 to
0.562. The values were generated directly from the disease-
specific I-QOL questionnaire by eliciting preferences
directly from a UK population. Eliciting preferences from a
condition-specific measure was favoured because mapping
algorithms (such as I-QOL to EQ-5D) have been found to
have poor predictive validity due to little overlap in the
classification systems of the condition-specific and generic
measures. The estimated mean utilities are in line with
published evidence indicating that utility in MS patients
was in the range of 0.1–0.92 [28], and that utility in the SCI
population was in the range of 0.394–0.667 [29]. In addi-
tion, differences between incontinent and continent (i.e.
dry) states correspond to those in previously published
models, which have reported such utility differences
ranging from 0.19 to 0.33 [30–34]. Scenario analyses,
based on published utility estimates of 0.66–0.78 [35] and
of 0.19–0.33 (obtained from studies in patients with over-
active bladder/UI) [30–34], increase the ICER; however,
onabotulinumtoxinA ? BSC still maintains its cost effec-
tiveness in line with the NICE threshold at £20,000 per
QALY gained.
The most common AEs observed in the trials were
UTIs. These were identified as being important because of
the clinical relationship with the rates of UI episodes [1,
36]. The model includes UTIs at week 12 of the clinical
trials. AEs were accounted for in the model only in terms
of costs; no disutility was applied, given the limited evi-
dence in the NDO population. In addition, as disutilities
were embedded in the trial data used to generate the health
state utilities, they were not included in the model, to avoid
double counting. It should be noted that the trial definition
of UTI was conservatively based on urinalysis and
microscopy and not on clinical symptoms. As the latter
were not recorded, it is not possible to say what proportion
of UTIs found in the trial would be classified as UTIs in
clinical practice, but it is likely that it would be\100 %, as
asymptomatic bacteriuria or leukocyturia are common,
especially in patients using CIC.
Finally, efficacy and safety assumptions were based on a
pooled study dataset (ITT) within the first 12 weeks after
treatment initiation. This time point was the furthest after
treatment initiation at which randomization integrity was
maintained—that is, no crossover from the BSC group to
the onabotulinumtoxinA ? BSC group. After week 12,
patients in the studies were allowed to receive re-treatment
if they requested it at any subsequent visit, provided that
they met the re-treatment criteria. Therefore, beyond
week 12, the trial population would consist of a mixture of
patients who had had one or more treatments. Week 12,
therefore, represents the most valid time point for com-
paring the efficacy of the two treatment options; these data
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were extrapolated to a 5-year time horizon. To allow
extrapolation beyond this short-time horizon, long-term
efficacy data for onabotulinumtoxinA are needed.
5 Conclusion
OnabotulinumtoxinA ? BSC is associated with a utility
benefit that is reflected in the reduction in the number of UI
episodes experienced by patients. For adult patients with
NDO who are not adequately managed with ACHDs, on-
abotulinumtoxinA ? BSC, at £20,000/QALY, appears to
be a cost-effective use of resources in the UK NHS.
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